Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Calorie restriction & fasting
Research brief

30% calorie restriction in SIV-infected macaques: lower acute viremia, less gut immune activation on ART

In an abstract, four months of 30% calorie restriction in rhesus macaques was safe and changed metabolism broadly; after SIV infection it reduced acute-phase viremia and, during ART suppression, limited gastrointestinal immune activation, while blood SIV DNA stayed unchanged. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Four months of 30% calorie restriction was safe and caused broad systemic metabolic reprogramming in healthy adult male and female rhesus macaques, compared with ad libitum feeding. [1]

  2. After SIV infection, calorie restriction reduced acute-phase viremia and dampened type I interferon signaling; the early viremia reduction associated with glycolysis ultimately waned over time. [1]

  3. During ART suppression, calorie restriction limited gastrointestinal immune activation and lowered soluble CD14 and TNF-related plasma molecules, but blood SIV DNA levels were unchanged. [1]

The source at a glance

Study type / format
Animal study (non-human primate model), reported in an abstract
Population / context
Healthy adult male and female rhesus macaques in a non-human primate model of HIV-1, later infected with SIV.
Summary based on
Study abstract
Publication status
Preprint · peer-review status not confirmed
Original publication
March 12, 2026

Calorie restriction before SIV in macaques

The abstract describes a non-human primate model of HIV-1. Healthy adult male and female rhesus macaques received 30% calorie restriction for four months; the comparison group was fed ad libitum. The authors report this was safe and produced broad, systemic metabolic reprogramming. Calorie restriction lowered the frequency of target CCR5+ CD4 T cells in the gut mucosa relative to ad libitum-fed animals. These measurements came before infection, so they describe the pre-infection state, not an outcome of SIV.

Supporting source [1]

Acute viremia and CD8 T cells after SIV

After infection with SIV, calorie restriction reduced acute-phase viremia and dampened type I interferon signaling. Overall it permitted more vigorous cycling of CD8+ T cells in lymphoid tissues. The protection was associated with a strong up-regulation of glycolysis, which supported an early reduction in viremia that ultimately waned over time. The abstract thus describes a temporally limited association, not a lasting antiviral effect.

Supporting source [1]

Gut immune activation under ART, unchanged SIV DNA

During virologic suppression with antiretroviral therapy, calorie restriction significantly limited gastrointestinal immune activation, improved flux through the tricarboxylic acid cycle and lowered plasma concentrations of soluble CD14 and several TNF-related molecules. Blood SIV DNA levels, however, were unchanged by calorie restriction. The authors interpret this as suggesting that residual gastrointestinal dysfunction and inflammation can be decoupled from viral persistence. These are associations in an animal model, not proven causes or human outcomes.

Supporting source [1]

How to interpret this

This explainer is based only on the abstract; the full text was not reviewed. The abstract reports an animal (rhesus macaque) study, so the findings are associations in a non-human primate model and do not establish causes or benefits for people. Sample sizes, follow-up details and statistical uncertainty are not given in the abstract.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Metabolic reprogramming by caloric restriction enhances acute phase virological control and reduces chronic inflammation in SIV-infected rhesus macaques

Suresh Babu N, Perdios C, Hallmets M, Brown AT, Coleman C, Fennessey CM, Allers C, Moström MJ, Khare P, Zhang C, Smith BT, Golden NA, Myers A, Doyle-Meyers L, Blaney A, Blair RV, Saied AA, Colman R, Keele BF, Le A, Palmer CS, Mudd JC. · europepmc.org · March 12, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    Four months of 30% CR was safe
  2. Finding 2 ↑

    reduced acute phase viremia, dampened type I
  3. Finding 3 ↑

    Blood SIV DNA levels however were unchanged

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…